Not disillusioned at all Koo....merely realistic.  I have no doubt there are hundreds of small biotechs looking to take fund managers by the hand.  If apabetalone were being developed by Big Pharma I figure RVX-208 would have a significantly higher pipeline valuation than it does now.

 It is what it is, reality.  I liken it to a hockey player whose 5'8" trying to crack the NHL, it can be done...but its harder than it would be for a guy who's 6'2" with the same skill set.  

The sad part is that shares are currency....as we've just seen with the announced HL PP.  If our PPS was $4, $5....heck $10, then there would have been a lot less dilution.  But big Pharma players use their shares as currency as well, and when it comes to Fund Manager types and trying to get them to take the hand that's being offered....its hard to get them to pay attention when they're all goo-goo eyed over the Pfizers of the world that are courting them. 

Happy Sunday in any case....early November is right around the corner.